Showing results (71-80 of 106) with videos related to

Sort By:
Pageof 11
The Lancet. Oncology|July 2, 2018
Relapse of Wilms' tumour and detection methods: a retrospective analysis of the 2001 Renal Tumour Study Group-International Society of Paediatric Oncology Wilms' tumour protocol databaseJesper Brok, Marta Lopez-Yurda, Harm V Tinteren, et al.
Diagnostics (Basel, Switzerland)|January 21, 2022
A Metabonomic View on Wilms Tumor by High-Resolution Magic-Angle Spinning Nuclear Magnetic Resonance SpectroscopyLjubica Tasic, Nataša Avramović, Melissa Quintero, et al.
European Journal of Cancer (Oxford, England : 1990)|January 17, 2012
Prognostic stratification for children with hepatoblastoma: the SIOPEL experienceRudolf Maibach, Derek Roebuck, Laurence Brugieres, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2010
Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR studyJózsef Zsíros, Rudolf Maibach, Elizabeth Shafford, et al.
Pediatric Blood & Cancer|March 4, 2011
Malignant rhabdoid tumours of the kidney (MRTKs), registered on recent SIOP protocols from 1993 to 2005: a report of the SIOP renal tumour study groupMarry M van den Heuvel-Eibrink, Harm van Tinteren, Harriet Rehorst, et al.
Oncology|September 12, 2008
Molecular profiling of isolated histological components of wilms tumor implicates a common role for the Wnt signaling pathway in kidney and tumor developmentMariana Maschietto, Beatriz de Camargo, Helena Brentani, et al.
European Journal of Cancer (Oxford, England : 1990)|June 5, 2019
Evaluation of needle biopsy as a potential risk factor for local recurrence of Wilms tumour in the SIOP WT 2001 trialSabine Irtan, Harm Van Tinteren, Norbert Graf, et al.
Lancet (London, England)|July 13, 2015
Omission of doxorubicin from the treatment of stage II-III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trialKathy Pritchard-Jones, Christophe Bergeron, Beatriz de Camargo, et al.
The New England Journal of Medicine|October 23, 2009
Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastomaGiorgio Perilongo, Rudolf Maibach, Elisabeth Shafford, et al.
Revista Da Associacao Medica Brasileira (1992)|January 24, 2019
Epidemiological profile of Brazilian oncological patients seen by a reference oncology center of the public health system and who migrate in search of adequate health careDaniel I G Cubero, Cláudia Vaz de Melo Sette, Beatriz de Camargo Preto Piscopo, et al.
Pageof 11